<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829034</url>
  </required_header>
  <id_info>
    <org_study_id>824808</org_study_id>
    <nct_id>NCT02829034</nct_id>
  </id_info>
  <brief_title>Targeting Right Ventricle in Pulmonary Hypertension Gilead</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Using Cardiovascular MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking to see if giving ranolazine to subjects on stable pulmonary
      hypertension therapies but with right ventricular dysfunction (RVEF &lt;45%) will improve their
      health by improving right ventricular (RV) function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in right ventricle ejection fraction as assessed by MRI</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranolazine 500mg by mouth twice per day and after two weeks increase to 1000mg by mouth twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth twice per day for a total of 26 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic pulmonary hypertension based on one of the following criteria:

               -  Idiopathic pulmonary arterial hypertension

               -  Familial pulmonary arterial hypertension

               -  Pulmonary hypertension associated with connective tissue disease

               -  Chronic thromboembolic pulmonary hypertension-nonsurgical/distal vessel disease
                  or patients who are reluctant to go to surgery within a 6-month period and are
                  willing to participate

               -  Simple congenital such as repaired atrial septal defect or ventricular septal
                  defect or unrepaired small atrial septal defect or ventricular septal defect with
                  persistent and out of proportion pulmonary arterial hypertension

               -  Group 3 patients who have a component of pulmonary arterial hypertension
                  *Pulmonary hypertension caused by conditions affect the veins and small vessels
                  of the lungs

               -  Sickle cell disease

               -  Group 5 pulmonary hypertension such as polycythemia vera

               -  Essential thrombocythemia

               -  Sarcoidosis

               -  Vasculitis

               -  Metabolic disorder

          -  World Health Organization functional class II, III, or IV

          -  Mean pulmonary artery pressure &gt;25 mmHg at rest

          -  Pulmonary capillary wedge pressure or left ventricular end diastolic pressure &lt; 15
             mmHg

          -  Pulmonary vascular resistance &gt; 3 mmHg/L/min

          -  Right ventricle ejection fraction &lt; 45%

          -  6-minute walk test distance &gt; 50 meters

        Exclusion Criteria:

          -  Previous treatment with or prior sensitivity to ranolazine

          -  Any family history of corrected QT interval prolongation, congenital long QT syndrome,
             or receiving drugs that prolong the corrected QT interval

          -  Parenchymal lung disease showing total lung capacity &lt; 50% of predicted OR forced
             expiratory volume at one second/forced vital capacity &lt; 50%

          -  Portal hypertension associated with chronic liver disease

          -  Left sided heart disease including any of the following: moderate or greater aortic or
             mitral valve disease, Any left ventricle cardiomyopathy, Left ventricular systolic
             dysfunction defined as an ejection fraction &lt; 50%, Symptomatic coronary artery disease

          -  Uncontrolled systemic hypertension

          -  Implantable cardioverter-defibrillator, Pacemaker, hazardous metallic implants or any
             other contraindication to MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuchi Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuchi Han, MD</last_name>
    <email>yuchi.han@uphs.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Baer, MB, MBA</last_name>
    <email>baer2@mail.med.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gautam Ramani, MD</last_name>
      <email>gramani@medicine.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Luba Poliakova</last_name>
      <email>lpoliako@medicine.umaryland.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aaron Waxman, MD</last_name>
      <email>abwaxman@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Laurie Lawler, RN</last_name>
      <email>LLAWLER@PARTNERS.ORG</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuchi Han, MD</last_name>
      <email>yuchi.han@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Baer, MB, MBA</last_name>
      <email>baer2@mail.med.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary hypertension</keyword>
  <keyword>right ventricular function</keyword>
  <keyword>ranolazine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

